Literature DB >> 30930335

THROMBOTECT takes the lead.

Christoph Male1, Sarah H O'Brien2, Lesley Mitchell3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30930335      PMCID： PMC6442948          DOI： 10.3324/haematol.2018.209528

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

Review 1.  Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.

Authors:  E Vidal; A Sharathkumar; J Glover; E V S Faustino
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

2.  Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.

Authors:  Lesley Mitchell; Maureen Andrew; Kim Hanna; Thomas Abshire; Jacqueline Halton; John Wu; Ron Anderson; Irene Cherrick; Sunil Desai; Donald Mahoney; Patricia McCusker; Peter Chait; Mohamed Abdolell; Gabrielle de Veber; David Mikulis
Journal:  Thromb Haemost       Date:  2003-08       Impact factor: 5.249

3.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.